MedPath

Tagged News

Archetype Therapeutics to Present AI-Discovered Lung Cancer Drug Candidates at AACR 2025

AIDrug Discovery
  • Archetype Therapeutics will present in vivo proof-of-concept data for AI-identified small molecules targeting early-stage lung adenocarcinoma at the 2025 AACR Annual Meeting.
  • The company's generative AI platform identified novel and repurposed molecules that substantially outperform previously published compounds in preventing lung cancer invasion and metastasis.
  • Archetype is partnering with Abzena and Alloy Therapeutics to develop antibody-drug conjugates using clinical-stage and approved targeted therapy molecules discovered by their platform.
  • The Archetype platform enables virtual screening of billions of potential drugs per day in genomically-defined patient cohorts, advancing from AI-driven research to compelling in vivo data in just months.

Bayer Partners with ConcertAI to Accelerate Precision Oncology Drug Development Using AI

AIOncologyDrug Discovery
  • Bayer and ConcertAI have entered a multi-year strategic agreement leveraging AI and machine learning to accelerate clinical development in precision oncology.
  • The partnership utilizes ConcertAI's Translational360™ platform, which integrates data from over 9 million cancer patient records across the U.S., combining clinical, genomic, and imaging information.
  • This collaboration aims to enhance drug discovery by using multi-modal data and AI to better predict treatment responses, potentially delivering precision oncology treatments to patients faster.

1Cell.Ai Launches OncoIncytes: Revolutionary Multi-Modal Cancer Diagnostic Panel for Precision Oncology

AIOncology
  • 1Cell.Ai (formerly OneCell Diagnostics) has launched OncoIncytes, a comprehensive multi-modal cancer diagnostic panel that integrates ctDNA, CTCs, RNA transcriptomics, and proteomics data for enhanced precision oncology.
  • The technology employs a 1080 gene panel with AI and machine learning models, offering unprecedented sensitivity to optimize clinical trials, particularly for antibody-drug conjugate development.
  • Following a $16M Series A funding round, the company's rebranding reflects its evolution from genomics-based diagnostics to AI-powered precision oncology solutions aimed at revolutionizing cancer care.

Wearable Devices Receives U.S. Patent for Hybrid Voice and Gesture Control Technology

AI
  • Wearable Devices Ltd. received U.S. Patent and Trademark Office allowance for its "Gesture and Voice-Controlled Interface Device" patent, marking a significant advancement in the company's intellectual property portfolio.
  • The patented technology integrates gesture recognition with voice control interfaces, enabling personalized experiences through combined neural and voice-based user authentication for more secure human-machine interaction.
  • The innovation enables hands-free interaction across multiple applications including AR glasses navigation, smart home control, and clinical settings where medical professionals can interact with digital interfaces without compromising sterility.
  • The technology addresses limitations in current voice control systems by adding precision and personalization through intuitive gesture controls, creating a new dimension of seamless human-computer interaction.

iBio Licenses First-in-Class Antibody Targeting Activin E for Obesity and Cardiometabolic Diseases

AI
  • iBio has secured a licensing agreement with AstralBio for a preclinical first-in-class antibody targeting Activin E, discovered using iBio's patented Machine-Learning Antibody Engine.
  • Preclinical studies demonstrated the antibody's ability to induce fat-selective weight loss while preserving muscle mass, with synergistic effects when combined with GLP-1 receptor agonists.
  • The novel therapeutic approach could potentially reverse obesity, prevent diabetes, and improve cardiometabolic health by inhibiting Activin E-mediated signaling that regulates energy balance and fat distribution.

Neurovation Labs Secures Patent for Novel PTSD Biomarker Detection Technology

AINeurologyPrecision Medicine
• Neurovation Labs has been granted U.S. Patent No. 12,274,761 for technology that detects GluA1-containing AMPA receptors in the brain, enabling objective PTSD diagnosis.
• The patented radiological imaging device represents a significant advancement in mental health diagnostics by providing a physiological biomarker for a condition traditionally diagnosed through subjective assessments.
• Beyond PTSD, Neurovation Labs is exploring applications of this technology for other neurological conditions including traumatic brain injury, Alzheimer's disease, and epilepsy.

Kyowa Hakko Kirin Partners with InveniAI to Accelerate Drug Repurposing Using AI Technology

OncologyAIDrug Discovery
  • Kyowa Hakko Kirin has signed a partnership with AI company InveniAI to use their AlphaMeld technology for discovering new therapeutic applications for existing pipeline drugs.
  • The collaboration focuses on maximizing R&D value in oncology, nephrology, and immunology by identifying alternate uses for drugs including mogamulizumab, istradefylline, and entinostat.
  • This partnership represents part of a growing trend where pharmaceutical companies are leveraging AI platforms to reduce development costs and accelerate time to market for drug candidates.

PGxAI Launches Deneb: AI Model to Revolutionize Drug Development Through Pharmacogenetics

AIPrecision Medicine
  • PGxAI has introduced Deneb, an advanced AI model that integrates molecular structures, physicochemical properties, and genetic profiles to deliver real-time pharmacogenetic recommendations for drug development.
  • The new platform helps biopharmaceutical companies and CROs identify optimal patient cohorts, refine dosing strategies, and predict adverse reactions before clinical trials begin, significantly reducing development costs and failures.
  • By automating traditionally manual PGx guideline creation processes, Deneb enables more targeted, data-driven approaches to drug development, potentially accelerating regulatory approvals and bringing safer therapies to market faster.

Abu Dhabi Launches Multi-Partner Initiative to Advance Precision Medicine and Genomic Healthcare

Precision MedicineAI
  • Abu Dhabi's Department of Health signed a landmark MoU with six major partners including PureHealth, M42, Illumina, and leading universities to establish a collaborative framework for precision medicine and advanced therapies.
  • The partnership will focus on building genomic infrastructure tailored to Emirati populations, launching R&D initiatives in gene therapy and cell-based treatments, and integrating AI platforms for genomic data analysis.
  • This initiative builds on Abu Dhabi's existing Emirati Genome Programme, which has already collected over 430,000 genome samples, positioning the emirate as a global life sciences hub.
  • The collaboration aims to transform healthcare from a one-size-fits-all approach to deeply personalized, preventive care targeting oncology, rare genetic diseases, and metabolic disorders.

FDA Announces Shift from Animal Testing to AI Models, Boosting Recursion Pharmaceuticals Stock 20%

AIDrug DiscoveryMonoclonal Antibody
  • The FDA announced plans to replace animal testing with AI models and other human-relevant methods for drug development, initially focusing on monoclonal antibodies before expanding to other drug types.
  • Recursion Pharmaceuticals stock surged approximately 20% following the FDA announcement, as the company operates one of the largest biopharmaceutical datasets with over 60 petabytes of data for AI-driven drug discovery.
  • The regulatory shift could increase interest from other drugmakers in partnering with Recursion, which already collaborates with four major pharmaceutical companies including Bayer, Merck KGaA, Genentech, and Sanofi.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.